Join our presentation at the BIO Asia-Taiwan 2026 Conference
We’re excited to announce that Dr. Art Hsing-Mao Chu, CEO of T-E PHARMA, will be presenting at the Investment Summit […]
Meeing
R&D Progress
TE-1182 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan
“The development of TE-1182, an ADC for the treatment of HER2-resistant tumors” was selected as a significant case of the
Scientific Publication
Our Core Technology Platform Published in the Journal of the Chinese Chemical Society
T-E Pharma is honored to be invited by the Journal of the Chinese Chemical Society (JCCS) to publish a review
News
T-E Pharma Launches Pre-IPO Capital Raise Pursuing a Dual-Engine Strategy in Metabolic and Oncology Therapeutics; Targeting TPEx Emerging Stock Board Listing in Q4 2026
T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the
Scientific Publication
Our Latest Research Published in International Journal of Pharmaceutics
Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more
Meeing
Join our presentation at the BIOLOGICS WORLD TAIWAN 2026
We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the
R&D Progress
TE-6168 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan
“The development of TE-6168, the novel thrombolytic fusion protein” was selected as a significant case of the Center for Drug
News
T-E Pharma Hosts Annual Year-End Gala as Five Drug Candidates Reach Key Development Milestones
T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future
Reported
An Interview with Chairman Tse-Wen Chang, Founder of Immunwork and T-E Meds: A Journey Through Science and Entrepreneurship
Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard
Scientific Publication
Our Latest Research Published in Haematologica
Great news! Our latest publication presents TE-1146 as a novel therapeutic strategy for the treatment of multiple myeloma. We are